Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142506 · ClinicalTrials.gov registry record · Phase 3
Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
A Phase 3 study of Prostate Cancer and Erectile Dysfunction, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
- 5
- Study locations
NCT00142506 is a Phase 3 study of Prostate Cancer and Erectile Dysfunction that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 290 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (52% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT00142506, a Phase 3 study of Prostate Cancer and Erectile Dysfunction, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
- 5
- Study locations
Study Summary
Radiation sometimes affects the ability for a person to have a normal erection. Complete loss of erections after radiation treatment can happen in 40-50% of treated patients. There are medications, like sildenafil (also known as Viagra), that can help the ability to get back erections in almost 70% of such patients. The purpose of this study is to see if taking Viagra every day starting right before, during and for about 6 months after treatment, could reduce the risk of long-term erectile dysfunction.
Conditions Studied
Interventions
- DRUG sildenafil citrate and questionaires
- DRUG placebo tablets and questionaires
Study Locations (5)
New York
- Memorial Sloan-Kettering Cancer Center at Commack - Commack
- Memorial Sloan-Kettering Cancer Center - New York
- Memorial Sloan-Kettering Cancer Center at Mercy Medical Center - Rockville Centre
- Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center - Sleepy Hollow
New Jersey
- Memorial Sloan-Kettering Cancer Center at Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2005-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142506
The ClinicalTrials.gov registry entry for NCT00142506 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (52% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which sildenafil citrate and questionaires is the first listed.
NCT00142506 reports 5 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00142506 about?
NCT00142506 is a clinical study titled "Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer". Radiation sometimes affects the ability for a person to have a normal erection. Complete loss of erections after radiation treatment can happen in 40-50% of treated patients. There are medications, like sildenafil (also known as Viagra), that can help the ability to get back erections in almost 70% ...
What is the current status of trial NCT00142506?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2005-02. Estimated completion is 2014-04.
What conditions does trial NCT00142506 study?
This clinical trial studies the following conditions: Prostate Cancer, Erectile Dysfunction.
What interventions are being tested in trial NCT00142506?
The interventions under investigation include: sildenafil citrate and questionaires (DRUG), placebo tablets and questionaires (DRUG).
Who is sponsoring clinical trial NCT00142506?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00142506 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.